Equity (Details) - USD ($)							1 Months Ended			3 Months Ended		6 Months Ended
	Dec. 14, 2021	Aug. 13, 2021	Feb. 09, 2021	Feb. 06, 2021	Dec. 08, 2020	Nov. 03, 2020	Feb. 28, 2021	Jan. 27, 2021	Sep. 17, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Jan. 18, 2022	Jan. 04, 2022	Mar. 16, 2021	Nov. 02, 2020
Equity (Details) [Line Items]
Purchase price per shares (in Dollars per share)			$ 7.8	$ 6.805						$ 1		$ 1
Aggregate shares of common stock					1,560,000							100,000
Shares of common stock						one
Offering cost (in Dollars)						$ 1,430,000
Warrants exercise price (in Dollars per share)	$ 4					$ 1.99
Warrants expire term						5 years 6 months
Common stock price per share (in Dollars per share)						$ 5.97
Common stock issued						60,000
Consecutive trading days						20 days
Purchase price					3.1
Aggregate net proceeds (in Dollars)			$ 26,100,000	$ 12,400,000	$ 4,836,000							$ 4,563,908	$ 5,433,399
Exercise price (in Dollars per share)					$ 3.1
Term expire			5 years 6 months	5 years 6 months	3 years 6 months
Aggregate shares of common stock	3,228,807		3,655,000	1,998,500				1,086,956
Net proceeds of offering (in Dollars)												4,563,908
Purchase price for common stock and warrants (in Dollars per share)	$ 3.26							$ 3.68
Exercise price (in Dollars per share)								$ 5
Warrant exercise term, description								The net proceeds to the Company from such Offering were approximately $4.0 million. The purchase price for each share of common stock and five warrants is $3.68, and the exercise price per warrant is $5.00. The Warrants will be exercisable at any time during the period beginning on or after July 27, 2021 and ending on or prior on January 27, 2026 but not thereafter; provided, however, that the total number of the Company’s issued and outstanding shares of Common Stock, multiplied by the NASDAQ official closing bid price of the Common Stock shall equal or exceed $0.3 billion for a three consecutive month period prior to an exercise.On February 6, 2021, the Company entered into a securities purchase agreement with the investors pursuant to which the Company sold to the investors, and the investors purchased from the Company, in a registered direct offering, an aggregate of 1,998,500 shares of the common stock of the Company, no par value per share, at a purchase price of $6.805 per share. Net proceeds to the Company from the sale of the shares and the warrants, after deducting estimated offering expenses and placement agent fees, were approximately $12.4 million. The Company also sold to the investors warrants to purchase up to an aggregate of 1,998,500 shares of common stock at an exercise price of $6.805 per share. The warrants shall be initially exercisable upon issuance and expire five and a half (5.5) years from the date of issuance. The exercise price and the number of shares of common stock issuable upon exercise of the warrants are subject to adjustment in the event of stock splits or dividends, or other similar transactions, but not as a result of future securities offerings at lower prices. On February 9, 2021, the Company entered into a securities purchase agreement with the investors pursuant to which the Company sold to the investors, and the investors purchased from the Company, in a registered direct offering, an aggregate of 3,655,000 shares of the common stock of the Company, no par value per share, at a purchase price of $7.80 per share. Net proceeds to the Company from the sale of the shares and the warrants, after deducting estimated offering expenses and placement agent fees, were approximately $26.1 million. The Company also sold to the investors warrants to purchase up to an aggregate of 3,655,000 shares of common stock at an exercise price of $7.80 per share. The warrants shall be initially exercisable upon issuance and expire five and a half (5.5) years from the date of issuance. The exercise price and the number of shares of common stock issuable upon exercise of the warrants are subject to adjustment in the event of stock splits or dividends, or other similar transactions, but not as a result of future securities offerings at lower prices. On December 14, 2021, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with non-U.S. investors and accredited investors pursuant to which the Company agreed to sell to the Investors, and the Investors agreed to purchase from the Company, an aggregate of 3,228,807 shares of common stock, no par value, and warrants to purchase 4,843,210 shares. The purchase price for each share of common stock and one and a half warrants is $3.26, and the exercise price per Warrant is $4.00. The Warrants will be exercisable at any time during the Exercise Window.
Common stock exercise price (in Dollars per share)			$ 7.8	$ 6.805
Price of common stock (in Dollars)										$ 150,000,000		$ 150,000,000
Consecutive month												3 months
Shares issued										1,400,000		1,400,000
Remaining proceed (in Dollars)														$ 1,828,807	$ 5,961,911
Stock based compensation, description		(the “Company”) and the Compensation Committee of the Board (the “Committee”) approved a one-time award of a total of 1,020,000 shares of common stock from the shares reserved under the Company’s 2014 Stock Incentive Plan (the “Plan”) as follows: (i) Chief Executive Officer, Lei Cao, is entitled to a one-time stock award grant of 600,000 shares, (ii) acting Chief Financial Officer, Tuo Pan, is entitled to a one-time stock award grant of 200,000 shares, (iii) Board member, Zhikang Huang, is entitled to a one-time stock award grant of 160,000 shares, (iv) Board member, Jing Wang, is entitled to a one-time stock award grant of 20,000 shares, (v) Board member, Xiaohuan Huang, is entitled to a one-time stock award grant of 20,000 shares, and (vi) Board member, Tieliang Liu, is entitled to a one-time stock award grant of 20,000 shares.
Grant date fair value (in Dollars)		$ 2,927,400								$ 377,000		$ 377,000
Stock-based compensation expense (in Dollars)										$ 377,000		$ 3,304,400
Warrant [Member]
Equity (Details) [Line Items]
Aggregate shares of common stock				1,998,500
Purchase of warrants	4,843,210								720,000
Purchase price per share (in Dollars per share)									$ 1.46
Net proceeds (in Dollars)									$ 1,050,000.00
Warrants price per share (in Dollars per share)																$ 1.825
Description of warrant rights									The warrants will expire on March 16, 2026. The warrants are subject to anti-dilution provisions to reflect stock dividends and splits or other similar transactions. The warrants contain a mandatory exercise right for the Company to force exercise the warrants if the Company’s common stock trades at or above $4.38 for 20 consecutive trading days, provided, among other things, that the shares issuable upon exercise of the are registered or may be sold pursuant to Rule 144 and the daily trading volume exceeds 60,000 shares of common stock per trading day on each trading day in a period of 20 consecutive trading days prior to the applicable date.On November 2 and November 3, 2020, the Company issued an aggregate of 860,000 shares of Series A Convertible Preferred Stock (the “Series A Preferred Stock”), each convertible into one share of common stock, no par value, of Company, upon the terms and subject to the limitations and considerations set forth in the Certificate of Designation of the Series A Preferred Stock, and warrants to purchase up to 1,032,000 shares of common stock. The purchase price for each share of Series A Preferred Stock and accompanying warrants is $1.66. The net proceeds to the Company from this offering was approximately $1.43 million, not including any proceeds that may be received upon cash exercise of the warrants. The warrants will be exercisable six (6) months following the date of issuance at an exercise price of $1.99 for cash. The warrants may also be exercised cashlessly if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the warrant Shares. The warrants will expire five and a half (5.5) years from the date of issuance. The warrants are subject to anti-dilution provisions to reflect stock dividends and splits or other similar transactions.
Aggregate shares of common stock			3,655,000					5,434,780
Net proceeds of offering (in Dollars)								$ 4,000,000
Common Stock [Member]
Equity (Details) [Line Items]
Preferred stock conversion							860,000
Securities Purchase Agreements [Member]
Equity (Details) [Line Items]
Aggregate shares of common stock					1,170,000				720,000
Series A Convertible Preferred Stock [Member]
Equity (Details) [Line Items]
Warrants price per share (in Dollars per share)						$ 1.66
Aggregate issued shares																	860,000
Warrants to purchase of common stock						1,032,000
Preferred stock conversion							860,000